Eleftheria Kleio Dermitzaki

Suggest Changes
Learn More
BACKGROUND Erlotinib has been approved for the management of NSCLC patients after failure of the first or subsequent line of chemotherapy. Although the efficacy of erlotinib is clearly associated(More)
  • 1